Psyence Biomedical Ltd. Files 6-K with Key Agreements and Nasdaq News
Ticker: PBMWW · Form: 6-K · Filed: Nov 22, 2024 · CIK: 1985062
Sentiment: neutral
Topics: corporate-action, legal-agreement, listing-news
TL;DR
Psyence Biomedical Ltd. filed a 6-K detailing a termination agreement and positive Nasdaq listing news.
AI Summary
Psyence Biomedical Ltd. filed a Form 6-K on November 22, 2024, reporting on several key events. These include a Termination Agreement dated November 21, 2024, a press release from November 19, 2024, announcing the effective date of a share consolidation, and another press release from November 20, 2024, detailing a favorable Nasdaq listing qualifications hearing. An investor presentation dated November 2024 is also included.
Why It Matters
This filing provides updates on significant corporate actions, including a termination agreement and positive developments regarding Nasdaq listing, which could impact investor confidence and the company's trading status.
Risk Assessment
Risk Level: medium — The filing includes a termination agreement and news about Nasdaq listing qualifications, which can introduce uncertainty or positive momentum for the stock.
Key Players & Entities
- Psyence Biomedical Ltd. (company) — Registrant
- November 21, 2024 (date) — Termination Agreement Date
- November 19, 2024 (date) — Share Consolidation Press Release Date
- November 20, 2024 (date) — Nasdaq Listing Hearing Press Release Date
- Nasdaq (company) — Listing Exchange
FAQ
What is the nature of the Termination Agreement dated November 21, 2024?
The filing lists 'Termination Agreement, by and between the Company and the Signatories thereto, dated November 21, 2024' as Exhibit 10.1, but the specific details of the agreement are not provided in this summary.
When was the share consolidation effective?
The press release announcing the effective date of the share consolidation is dated November 19, 2024.
What was the outcome of the Nasdaq listing qualifications hearing?
The press release dated November 20, 2024, announces the 'Favorable Result of Nasdaq Listing Qualifications Hearing'.
What is Psyence Biomedical Ltd.'s principal executive office address?
The principal executive office is located at 121 Richmond Street West Penthouse Suite 1300, Toronto, Ontario M5H 2K1.
What other documents are included in this 6-K filing?
The filing includes Exhibit 4.1 (Form of Common Share Purchase Warrant), Exhibit 10.1 (Termination Agreement), Exhibit 99.1 (Press Release on Share Consolidation), Exhibit 99.2 (Press Release on Nasdaq Hearing), and Exhibit 99.3 (Investor Presentation).
Filing Stats: 206 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-11-22 08:05:02
Filing Documents
- tm2429142d1_6k.htm (6-K) — 10KB
- tm2429142d1_ex4-1.htm (EX-4.1) — 78KB
- tm2429142d1_ex10-1.htm (EX-10.1) — 43KB
- tm2429142d1_ex99-1.htm (EX-99.1) — 13KB
- tm2429142d1_ex99-2.htm (EX-99.2) — 13KB
- tm2429142d1_ex99-3.htm (EX-99.3) — 59KB
- tm2429142d1_ex99-3img001.jpg (GRAPHIC) — 147KB
- tm2429142d1_ex99-3img002.jpg (GRAPHIC) — 460KB
- tm2429142d1_ex99-3img003.jpg (GRAPHIC) — 165KB
- tm2429142d1_ex99-3img004.jpg (GRAPHIC) — 480KB
- tm2429142d1_ex99-3img005.jpg (GRAPHIC) — 106KB
- tm2429142d1_ex99-3img006.jpg (GRAPHIC) — 159KB
- tm2429142d1_ex99-3img007.jpg (GRAPHIC) — 121KB
- tm2429142d1_ex99-3img008.jpg (GRAPHIC) — 184KB
- tm2429142d1_ex99-3img009.jpg (GRAPHIC) — 169KB
- tm2429142d1_ex99-3img010.jpg (GRAPHIC) — 161KB
- tm2429142d1_ex99-3img011.jpg (GRAPHIC) — 144KB
- tm2429142d1_ex99-3img012.jpg (GRAPHIC) — 290KB
- tm2429142d1_ex99-3img013.jpg (GRAPHIC) — 206KB
- tm2429142d1_ex99-3img014.jpg (GRAPHIC) — 74KB
- tm2429142d1_ex99-3img015.jpg (GRAPHIC) — 196KB
- tm2429142d1_ex99-3img016.jpg (GRAPHIC) — 107KB
- tm2429142d1_ex99-3img017.jpg (GRAPHIC) — 135KB
- tm2429142d1_ex99-3img018.jpg (GRAPHIC) — 157KB
- tm2429142d1_ex99-3img019.jpg (GRAPHIC) — 226KB
- tm2429142d1_ex99-3img020.jpg (GRAPHIC) — 177KB
- tm2429142d1_ex99-3img021.jpg (GRAPHIC) — 173KB
- tm2429142d1_ex99-3img022.jpg (GRAPHIC) — 114KB
- tm2429142d1_ex99-3img023.jpg (GRAPHIC) — 89KB
- tm2429142d1_ex99-3img024.jpg (GRAPHIC) — 155KB
- tm2429142d1_ex99-3img025.jpg (GRAPHIC) — 152KB
- tm2429142d1_ex99-3img026.jpg (GRAPHIC) — 184KB
- tm2429142d1_ex99-3img027.jpg (GRAPHIC) — 206KB
- tm2429142d1_ex99-3img028.jpg (GRAPHIC) — 213KB
- tm2429142d1_ex99-3img029.jpg (GRAPHIC) — 288KB
- tm2429142d1_ex99-3img030.jpg (GRAPHIC) — 139KB
- tm2429142d1_ex99-3img031.jpg (GRAPHIC) — 210KB
- tm2429142d1_ex99-3img032.jpg (GRAPHIC) — 159KB
- tm2429142d1_ex99-3img033.jpg (GRAPHIC) — 159KB
- 0001104659-24-121840.txt ( ) — 8635KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-41937 Psyence Biomedical Ltd. (Translation of registrant’s name into English) 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBIT INDEX Exhibit Description 4.1 Form of Common Share Purchase Warrant 10.1 Termination Agreement, by and between the Company and the Signatories thereto, dated November 21, 2024. 99.1 Press Release, dated November 19, 2024, Announcing Effective Date of Share Consolidation. 99.2 Press Release, dated November 20, 2024, Announcing the Favorable Result of Nasdaq Listing Qualifications Hearing 99.3 Investor Presentation, dated November 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: November 22, 2024 Psyence Biomedical Ltd. By: /s/ Dr. Neil Maresky Name: Dr. Neil Maresky Title: Chief Executive Officer and Director